JP2018511634A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511634A5 JP2018511634A5 JP2017553956A JP2017553956A JP2018511634A5 JP 2018511634 A5 JP2018511634 A5 JP 2018511634A5 JP 2017553956 A JP2017553956 A JP 2017553956A JP 2017553956 A JP2017553956 A JP 2017553956A JP 2018511634 A5 JP2018511634 A5 JP 2018511634A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- cancer
- dihydro
- solvent
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021009106A JP7383652B2 (ja) | 2015-04-15 | 2021-01-22 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
| JP2023190552A JP2024012540A (ja) | 2015-04-15 | 2023-11-08 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015076639 | 2015-04-15 | ||
| CNPCT/CN2015/076639 | 2015-04-15 | ||
| PCT/CN2016/079251 WO2016165626A1 (en) | 2015-04-15 | 2016-04-14 | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021009106A Division JP7383652B2 (ja) | 2015-04-15 | 2021-01-22 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018511634A JP2018511634A (ja) | 2018-04-26 |
| JP2018511634A5 true JP2018511634A5 (OSRAM) | 2019-05-23 |
| JP7320741B2 JP7320741B2 (ja) | 2023-08-04 |
Family
ID=57125563
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553956A Active JP7320741B2 (ja) | 2015-04-15 | 2016-04-14 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
| JP2021009106A Active JP7383652B2 (ja) | 2015-04-15 | 2021-01-22 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
| JP2023190552A Withdrawn JP2024012540A (ja) | 2015-04-15 | 2023-11-08 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021009106A Active JP7383652B2 (ja) | 2015-04-15 | 2021-01-22 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
| JP2023190552A Withdrawn JP2024012540A (ja) | 2015-04-15 | 2023-11-08 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10351559B2 (OSRAM) |
| EP (2) | EP3283486B1 (OSRAM) |
| JP (3) | JP7320741B2 (OSRAM) |
| KR (2) | KR102643609B1 (OSRAM) |
| CN (2) | CN107531682B (OSRAM) |
| AU (1) | AU2016248376B2 (OSRAM) |
| CA (1) | CA2981746C (OSRAM) |
| EA (1) | EA035680B1 (OSRAM) |
| IL (2) | IL255555B (OSRAM) |
| MX (1) | MX381053B (OSRAM) |
| NZ (1) | NZ735715A (OSRAM) |
| SG (1) | SG11201707984TA (OSRAM) |
| TW (4) | TWI876835B (OSRAM) |
| WO (1) | WO2016165626A1 (OSRAM) |
| ZA (1) | ZA201706392B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973025B2 (en) | 2005-05-26 | 2011-07-05 | Neuron Systems, Inc. | Compositions and methods of treating retinal disease |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| HRP20160641T1 (hr) | 2011-12-31 | 2016-09-23 | Beigene, Ltd. | Fuzionirani triciklički spojevi kao inhibitori raf kinaze |
| HK1217439A1 (zh) | 2013-01-23 | 2017-01-13 | Aldeyra Therapeutics, Inc. | 与毒性醛相关的疾病和治疗 |
| TWI876835B (zh) | 2015-04-15 | 2025-03-11 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶抑制劑的馬來酸鹽、其結晶形式及用途 |
| MX2018002155A (es) | 2015-08-21 | 2018-06-08 | Aldeyra Therapeutics Inc | Compuestos deuterados y usos de los mismos. |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| CN110494166B (zh) | 2017-05-02 | 2022-11-08 | 诺华股份有限公司 | 组合疗法 |
| JP7311162B2 (ja) | 2017-10-10 | 2023-07-19 | アルデイラ セラピューティクス， インコーポレイテッド | 炎症性障害の処置 |
| WO2020033344A1 (en) * | 2018-08-06 | 2020-02-13 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| GEP20237494B (en) * | 2018-10-31 | 2023-04-10 | Servier Lab | Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same |
| CN111484489B (zh) * | 2019-01-25 | 2023-05-23 | 百济神州(北京)生物科技有限公司 | 无定形的b-raf激酶二聚体抑制剂 |
| CN111484488A (zh) * | 2019-01-25 | 2020-08-04 | 百济神州(北京)生物科技有限公司 | 一种b-raf激酶二聚体抑制剂的稳定结晶形式a |
| CN113874017B (zh) * | 2019-03-15 | 2024-11-22 | 福马治疗股份有限公司 | 抑制环amp-应答元件结合蛋白(creb) |
| WO2020223685A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| KR102881316B1 (ko) | 2019-05-13 | 2025-11-05 | 노파르티스 아게 | 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태 |
| CN111184693B (zh) * | 2019-05-29 | 2023-07-21 | 百济神州(苏州)生物科技有限公司 | 一种raf激酶抑制剂制剂及其制备方法 |
| JP7748386B2 (ja) * | 2020-04-03 | 2025-10-02 | ベイジーン， リミテッド | がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与 |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| WO2023240178A1 (en) * | 2022-06-08 | 2023-12-14 | Mapkure, Llc | Methods of treating cancer with a b-raf inhibitor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5111113B2 (ja) | 2004-12-13 | 2012-12-26 | サネシス ファーマシューティカルズ， インコーポレイテッド | Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| WO2007067444A1 (en) | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| AU2007254325B2 (en) | 2006-05-15 | 2012-05-10 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2008023239A1 (en) | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
| US20080064729A1 (en) | 2006-09-07 | 2008-03-13 | Millennium Pharmaceuticals, Inc. | Phenethylamide derivatives with kinase inhibitory activity |
| BRPI0811517A2 (pt) | 2007-05-04 | 2014-11-18 | Irm Llc | Compostos e composições como inibidores de c-kit e pdgfr cinase. |
| US20100197924A1 (en) * | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| JP5808818B2 (ja) * | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| HRP20160641T1 (hr) | 2011-12-31 | 2016-09-23 | Beigene, Ltd. | Fuzionirani triciklički spojevi kao inhibitori raf kinaze |
| TWI876835B (zh) * | 2015-04-15 | 2025-03-11 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶抑制劑的馬來酸鹽、其結晶形式及用途 |
-
2016
- 2016-04-14 TW TW113101605A patent/TWI876835B/zh active
- 2016-04-14 KR KR1020177033101A patent/KR102643609B1/ko active Active
- 2016-04-14 CN CN201680021109.0A patent/CN107531682B/zh active Active
- 2016-04-14 EP EP16779601.0A patent/EP3283486B1/en active Active
- 2016-04-14 NZ NZ735715A patent/NZ735715A/en unknown
- 2016-04-14 TW TW112101259A patent/TWI832668B/zh active
- 2016-04-14 TW TW105111715A patent/TWI736531B/zh active
- 2016-04-14 KR KR1020247006890A patent/KR20240049684A/ko active Pending
- 2016-04-14 CN CN202110419671.1A patent/CN113307805A/zh active Pending
- 2016-04-14 US US15/565,807 patent/US10351559B2/en active Active
- 2016-04-14 EA EA201792254A patent/EA035680B1/ru unknown
- 2016-04-14 SG SG11201707984TA patent/SG11201707984TA/en unknown
- 2016-04-14 WO PCT/CN2016/079251 patent/WO2016165626A1/en not_active Ceased
- 2016-04-14 TW TW110125410A patent/TWI792406B/zh active
- 2016-04-14 JP JP2017553956A patent/JP7320741B2/ja active Active
- 2016-04-14 CA CA2981746A patent/CA2981746C/en active Active
- 2016-04-14 AU AU2016248376A patent/AU2016248376B2/en active Active
- 2016-04-14 EP EP22179294.8A patent/EP4119559A1/en active Pending
- 2016-04-14 MX MX2017013219A patent/MX381053B/es unknown
-
2017
- 2017-09-21 ZA ZA2017/06392A patent/ZA201706392B/en unknown
- 2017-11-09 IL IL255555A patent/IL255555B/en unknown
-
2021
- 2021-01-22 JP JP2021009106A patent/JP7383652B2/ja active Active
- 2021-10-31 IL IL287740A patent/IL287740B2/en unknown
-
2023
- 2023-11-08 JP JP2023190552A patent/JP2024012540A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018511634A5 (OSRAM) | ||
| JP2018528199A5 (OSRAM) | ||
| JP2020033359A5 (OSRAM) | ||
| AU2016260279B2 (en) | Crystals of azabicyclic compound | |
| TWI826373B (zh) | (s)-2-((2-((s)-4-(二氟甲基)-2-氧代唑烷-3-基)-5,6-二氫苯并[f]咪唑并[1,2-d][1,4]氧氮呯-9-基)胺基)丙醯胺之多晶型及固體形式及製造方法 | |
| JP2013518041A5 (OSRAM) | ||
| CN107531682A (zh) | B‑raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途 | |
| JP2020517611A5 (OSRAM) | ||
| JP2019515024A (ja) | ボルチオキセチンのパモ酸塩及びその結晶形 | |
| CA3009713A1 (en) | Crystalline forms of ponesimod and preparation method thereof | |
| CA3142088A1 (en) | Compound used as kinase inhibitor and application thereof | |
| JP7124035B2 (ja) | アクリジニウム臭化物の製造方法 | |
| AU2018372180B2 (en) | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production | |
| JP6816036B2 (ja) | ヒストン脱アセチル化阻害剤の結晶形態 | |
| JP2013541589A5 (OSRAM) | ||
| JP6676626B2 (ja) | アシルチオウレア化合物のメシル酸塩の結晶及びその製造方法 | |
| WO2016187028A1 (en) | Heteroaryl compounds, synthesis thereof, and intermediates thereto | |
| ES2727667T3 (es) | Polimorfos de lenalidomida | |
| JP2020530497A (ja) | ３−（５−フルオロベンゾフラン−３−イル）−４−（５−メチル−５Ｈ−［１，３］ジオキソロ［４，５−ｆ］インドール−７−イル）ピロール−２，５−ジオンの固体形態 | |
| CN111315748B (zh) | 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1,3]间二氧杂环戊烯并[4,5-f]吲哚-7-基)吡咯-2,5-二酮晶体 | |
| JP2015521635A5 (OSRAM) | ||
| JP6165335B2 (ja) | ゲフィチニブの新規な結晶形およびその製造方法 | |
| CA2561635C (en) | New crystalline form of 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | |
| JPWO2011152411A1 (ja) | チエノピリミジン誘導体の結晶 | |
| JP2010229098A (ja) | イソインドリン誘導体のａ型の結晶形の製造方法及びイソインドリン誘導体のａ型の結晶形 |